Share Transfer

RNS Number : 3560G

Premaitha Health PLC

05 November 2018

 

Premaitha Health plc

("Premaitha", the "Company" or the "Group")

Share Transfer

Manchester, UK - 5^th November 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces that is has been notified today that the wife of Dr. Bill Chang, Chief Scientific Officer of the Company, has transferred her shareholding in the Company, being 6,464,638 ordinary shares in the Company, to Dr Bill Chang's account on 2 November 2018. Dr. Chang's beneficial interest of 74,855,996 ordinary shares representing 17.92% of the Company's issued share capital remains unchanged.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
Premaitha Health PLC Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing [e-mail]	Tel: [phone]
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie	Tel: [phone]
finnCap (Broker) Geoff Nash / Matthew Radley (Corporate Finance) Tim Redfern (Corporate Broking)	Tel: [phone]
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock [e-mail]	Tel: [phone]

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests.

The Group's current primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market - although the Group intends to expand its product range into other areas of clinical genetics.

Premaitha's first product, the IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening solution that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Since May 2018, the Group has traded as Yourgene Health outside of Europe (but remains as Yourgene Bioscience in Taiwan), reflecting the increased scope of the business in other areas of clinical genetics further to reproductive health; but maintains the Premaitha Health brand within Europe.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

 

END

 

 

DSHBBBDBRBGBGIU